{"id":674,"date":"2020-11-27T07:10:36","date_gmt":"2020-11-27T07:10:36","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=674"},"modified":"2020-11-27T07:10:54","modified_gmt":"2020-11-27T07:10:54","slug":"23-nov-2020-interferons-peg-interferon-lambda-1a-did-not-shorten-the-duration-of-viral-shedding","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/23-nov-2020-interferons-peg-interferon-lambda-1a-did-not-shorten-the-duration-of-viral-shedding\/","title":{"rendered":"(23 Nov 2020) Interferons &#8211; PEG Interferon lambda 1a did not shorten the duration of viral shedding"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2020.11.18.20234161v1<\/p>\n<p class=\"\">In a randomized placebo-controlled trial <a class=\"external-ref external-ref-type-clintrialgov\" href=\"https:\/\/www.medrxiv.org\/lookup\/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT04331899&amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F11%2F23%2F2020.11.18.20234161.atom\">(NCT04331899 <\/a>)in 120 patients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) could shorten the duration of viral shedding (primary endpoint) or symptoms . In both the 60 patients receiving Lambda and the 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively (HR 0.94; 95% CI 0.64 to 1.39). At enrollment; 41% of subjects were SARS-CoV-2 IgG seropositive; compared to placebo, lambda tended to delay shedding cessation in seronegatives (aHR 0.66, 95% CI 0.39-1.10) and to hasten shedding cessation in seropositives (aHR 1.58, 95% CI 0.88-2.86; p for interaction = 0.03). Liver transaminase elevations were more common in the Lambda vs. placebo arm (15\/60 vs 5\/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial https:\/\/www.medrxiv.org\/content\/10.1101\/2020.11.18.20234161v1 In a randomized placebo-controlled trial (NCT04331899 )in 120 patients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/23-nov-2020-interferons-peg-interferon-lambda-1a-did-not-shorten-the-duration-of-viral-shedding\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(23 Nov 2020) Interferons &#8211; PEG Interferon lambda 1a did not shorten the duration of viral shedding&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,30],"tags":[31],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/674"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=674"}],"version-history":[{"count":2,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/674\/revisions"}],"predecessor-version":[{"id":676,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/674\/revisions\/676"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}